200 AI-Designed Drugs in Trials, None Approved Yet — Jun 8, 2026

Two hundred AI-designed drugs are now in human trials. Not one is approved.Run time: 20:11In today's episode:Two hundred AI-discovered drugs in trials, zero approvedFDA clears Clarius bedside ejection-fraction AIGE HealthCare auto-contouring tool cleared for radiation planningPhilips and WellSpan sign seven-year AI imaging allianceJoint Commission launches first hospital AI certificationWHO weighs AI for health-policy decisionsAnthropic scales Mythos cyber program to fifteen countriesPerplexity lets its agent write its own search codeOpenAI says chat is dead, pivots to agentsTL;DR:The AI drug-discovery story matured into a counting problem: 200-plus candidates in clinical trials, roughly 56 in Phase 2 and 15 in Phase 3, and still zero FDA approvals. The 2026 Phase 3 readouts (zasocitinib, more rentosertib data) are the real test.Two more FDA clearances landed this week — Clarius for bedside ejection fraction, GE HealthCare for radiation-oncology auto-contouring — both narrow, both incremental, both shipping into existing workflows rather than replacing anyone.Governance caught up to deployment: the Joint Commission's Responsible Use of AI certification went live June 1, the first accreditation-grade AI program built specifically for health systems.Sources cited:BioMed NexusDAICITNPhilipsJoint CommissionWHOTechCrunchThe Decoderthe AAPM TG-275/TG-132 segmentation guidance and reviews on auto-segmentation QASubscribe: YouTubemedAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.